AstraZeneca Acquires Modella AI in First Major Pharma-AI Deal to Accelerate Oncology Drug Development
核心洞察
AstraZeneca has agreed to acquire Boston-based Modella AI (搜索) in what the company claims is the first acquisition of an AI firm by a major pharmaceutical company.
The acquisition will integrate Modella's foundation models and AI agents into AstraZeneca's oncology (搜索) research to support clinical development and biomarker discovery efforts.
The deal expands a multi-year collaboration unveiled in July and aims to accelerate quantitative pathology and patient selection for drug trials to increase clinical success rates.
AstraZeneca has agreed to acquire Boston-based artificial intelligence company Modella AI (搜索), marking what the pharmaceutical giant claims is the first acquisition of an AI firm by a major pharmaceutical company. The companies announced the deal on Tuesday but did not disclose financial terms.
The acquisition represents a significant expansion of the drug industry's embrace of artificial intelligence to accelerate drug discovery and development processes. Modella AI (搜索)'s "foundation models" and AI agents will be integrated into AstraZeneca's oncology (搜索) research and development operations to support clinical development and biomarker discovery.
Strategic Focus on Quantitative Pathology
"Oncology (搜索) drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI (搜索)'s chief commercial officer. She noted that joining AstraZeneca would allow the company to deploy its tools in global trials and clinical settings.
AstraZeneca Chief Financial Officer Aradhana Sarin, speaking at the J.P. Morgan Healthcare Conference, said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal will accelerate AstraZeneca's efforts to make pathology more quantitative by using computers to analyze biopsies for relevant proteins and correlate them with clinical data. This approach aims to help AstraZeneca develop "highly targeted biomarkers and then highly targeted therapeutics," according to Sarin.
Building on Existing Partnership
The acquisition builds on a multi-year collaboration between the companies that was unveiled in July. Sarin described that partnership as serving as a "test drive," explaining that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
The integration of AI tools is expected to enable more rapid patient selection for drug trials, which could increase the odds of clinical success and reduce related costs, according to Sarin.
Industry-Wide AI Adoption
The AstraZeneca-Modella deal was announced alongside several other partnerships between major pharmaceutical companies and AI firms at the healthcare conference. Notably, Nvidia (搜索) and Eli Lilly announced a $1 billion collaboration to build a new research lab using Nvidia's latest-generation AI chips.
Future Outlook
During the conference, Sarin indicated that 2026 is expected to be another catalyst year for AstraZeneca, with multiple high-value late-stage readouts anticipated across therapy areas. The company is currently targeting $80 billion in annual revenue by 2030.